已收盘 08-01 16:00:00 美东时间
+1.370
+1.36%
Corbus Pharmaceuticals has initiated the multiple ascending dose (MAD) portion of its Phase 1 trial for CRB-913, a peripherally restricted CB1 inverse agonist for obesity treatment. The MAD study, scheduled to complete in Q3 2025, follows the single ascending dose (SAD) study, which showed no treatment-related neuropsychiatric events. The company plans to launch a Phase 1b dose-range finding study in obese individuals later this year. CRB-913 is ...
06-30 12:00
查看最新行情 继美国总统唐纳德·特朗普威胁对苹果公司征收关税后,苹果公司股价周五下跌,其供应商的股价也随之下挫。 相关新闻:特朗普向苹果发...
05-23 21:48
❶中润光学拟收购戴斯光电51%股权,交易对价为1.58亿元 中润光学近日发布公告称,公司拟使用自有资金和部分超募资金收购湖南戴斯光电有限公司51%的股权。本次交...
05-11 20:30
Corporate buybacks surged in April, led by Apple, Alphabet, and Wells Fargo, signaling confidence and boosting stock prices. Tech and consumer companies also joining the buyback binge.
05-09 00:18
每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。
05-08 08:45
Barclays analyst Tom O'Malley maintains Cirrus Logic (NASDAQ:CRUS) with a Equal-Weight and raises the price target from $80 to $90.
05-07 20:50
每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。
04-18 08:48
Analysts' ratings for Cirrus Logic (NASDAQ:CRUS) over the last quarter vary fro...
04-17 22:00
(原标题:Altera,何以至此?) 如果您希望可以时常见面,欢迎标星收藏哦~ 来源:内容编译自nextplatform,谢谢。 陷入困境的芯片制造商英特尔一直...
04-16 09:10